IDACORP, Inc. Announces First Quarter 2026 Results, Reaffirms 2026 Earnings Guidance

IDACORP, Inc. reported strong first-quarter 2026 net income of $68.0 million ($1.21 per diluted share), up from $59.6 million ($1.10 per diluted share) in Q1 2025, driven by customer growth and rate changes. The company reaffirmed its full-year 2026 earnings guidance in the range of $6.25 to $6.45 per diluted share, expecting less than $30 million in additional tax credits. These positive results are attributed to increased retail revenues, customer growth, and effective management despite higher O&M expenses.

Original reporting
Published Apr 30, 2026, 10:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 30, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
IDACORP, Inc. Announces First Quarter 2026 Results, Reaffirms 2026 Earnings Guidance — source image
Decision brief

The 30-second read

$IDABullishMed
01

Why it matters

The strong earnings and reaffirmed guidance reinforce the company's stability, potentially leading to increased investor confidence and stock appreciation.

02

Market read

The news is highly relevant for investors in the utility sector, indicating positive company performance and sector stability.

03

What to watch

Market volatility or macroeconomic factors such as interest rate hikes could dampen positive sentiment and affect stock performance.

Relevance 6/10Timing: Immediate to short-term (next 1-3 weeks)

Background

IDACORP, Inc. operates in the utility sector, providing electric services with a focus on customer growth and rate management.

Company-level read

Ticker impact

$IDABullishHigh confidence
Context

The news pertains directly to IDACORP, Inc., which is reflected in the positive sentiment and strong earnings report.

Expected impact

Moderate upward movement expected in the short to medium term, contingent on continued earnings performance.

Evidence & confidence

The earnings beat and reaffirmed guidance indicate solid operational performance, supported by favorable industry trends and customer growth.

Market effects

The positive earnings report from IDACORP may bolster investor confidence in the utility sector, potentially leading to sector-wide gains.

Limited regional impact; primarily affects investors and stakeholders within the company's operational regions.

Minimal direct global relevance; however, positive utility sector performance can influence broader market sentiment.

Counterpoint

Potential risks include rising operational costs or regulatory changes that could impact profitability, which are not reflected in current earnings.

Key entities

  • IDACORP, Inc.

    A utility company providing electric services.

  • Industry Analysts

    Experts who have reviewed the company's earnings and guidance.

Related articles

$IDAMedAI 8/10

IDACORP Q2 Profit Rises, Lifts FY26 Earnings Guidance

IDACORP reported Q2 net income of $102.6 million, or $1.79 per share, up from $95.8 million, or $1.76 per share a year earlier, citing customer growth and higher rates. Retail revenues per MWh fell to $27.5 from $44.0. For FY2026, it raised the lower end of EPS guidance to $6.30-$6.45 from $6.25-$6.45.

$IDAMed

IDACORP, Inc. Announces Second Quarter 2026 Results, Increases Lower-End of Earnings Guidance Range

IDACORP INC (IDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 July 30, 2026 IDACORP, Inc. Announces Second Quarter 2026 Results, Increases Lower-End of Earnings Guidance Range BOISE, Idaho--IDACORP, Inc. (NYSE: IDA) reported second quarter 2026 net income attributable to IDACORP of $102.6 million, or $1.79 per diluted share, co

$TRAXMedAI 8/10

First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics (TRAX) reported positive results from a Phase Ib study of ANB033 for celiac disease, showing significant symptom reduction and fewer adverse events compared to placebo. The company plans to present results at ICDS in November and expects cohort two data in Q1 2027. ANB033 targets both IL-15 and IL-2, differentiating it from other therapies. The FDA has granted Fast Track designation, and late-stage trials are anticipated in 2027.